Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, single-center, non-inferiority clinical trial with two parallel groups of 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) in combination with the combined Photodynamic therapy (PDT) (daylight PDT followed by conventional PDT) vs conventional Photodynamic therapy (PDT) in patients with actinic keratosis

Next Previous
Trial Profile

A randomized, single-center, non-inferiority clinical trial with two parallel groups of 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) in combination with the combined Photodynamic therapy (PDT) (daylight PDT followed by conventional PDT) vs conventional Photodynamic therapy (PDT) in patients with actinic keratosis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 05 Aug 2022 New trial record
  • 01 Jul 2022 Primary endpoint (Reduction of actinic keratosis, 12 weeks after treatment) not met, as per Results published in the Photodermatology Photoimmunology and Photomedicine.
  • 01 Jul 2022 Results published in the Photodermatology Photoimmunology and Photomedicine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top